Nie masz uprawnień do wyświetlenia tego obiektu. Aby poprosić o dostęp do niego, wypełnij poniższe pola.
Moćko, Paweł
2018
Praca doktorska
Introduction: Ulcerative colitis (UC) and Crohn disease (CD) are classified as nonspecific inflammatory bowel diseases (IBDs). The aim of the study was to compare the safety profile of biologic drugs in patients with IBDs.Methods: A systematic literature search was performed using PubMed, Embase, and CENTRAL. Randomized controlled trials comparing biologic drugs used in the treatment of patients with UC (infliximab, adalimumab, golimumab, and wedolizumab) or CD (infliximab, adalimumab, wedolizumab, certolizumab pegol, and ustekinumab) with placebo were analyzed. The safety profile of biologic drugs was assessed using a network meta-analysis (NMA). The NMA was performed separately for patients with UC and CD, and generally for patients with IBDs. The study was registered on PROSPERO (CRD42016032607, CRD42016032606, CRD42015029884).Results: For most comparisons and endpoints, the NMA showed no significant differences in the rate of adverse events. A significantly higher risk of injection site reaction was showed for adalimumab compared with placebo (patients with UC) and a significant advantage of certolizumab pegol over infliximab and placebo (patients with IBDs). Conclusion: There were no significant differences in the relative assessment of these drugs or in their safety profile, as compared with placebo.
Kraków
2 - studia doktoranckie
choroby układu trawiennego
Wydział Nauk o Zdrowiu
Pilc, Andrzej ; Kawalec, Paweł
2017
oai:dl.cm-uj.krakow.pl:4290
ZB-128494
pol; eng
tylko w bibliotece
17 mar 2023
29 maj 2019
69
1
http://www.dl.cm-uj.krakow.pl:8080/publication/4291
RDF
OAI-PMH
Brzozowski, Bartosz
Rozpondek, Piotr
Kaczmarczyk, Olga
Stawowczyk, Ewa
Szczeklik, Katarzyna
Herman, Roma
Holko, Przemysław
Styl cytowania: chicago-author-date iso690-author-date chicago-author-date
Ta strona wykorzystuje pliki 'cookies'. Więcej informacji Rozumiem